Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Invested Capital (2021 - 2025)

UroGen Pharma (URGN) has disclosed Return on Invested Capital for 5 consecutive years, with 0.74% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 423.0% year-over-year to 0.74%, compared with a TTM value of 0.74% through Dec 2025, up 423.0%, and an annual FY2025 reading of 6.58%, down 737.0% over the prior year.
  • Return on Invested Capital was 0.74% for Q4 2025 at UroGen Pharma, up from 0.64% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 7.76% in Q2 2024 and bottomed at 3.49% in Q4 2024.
  • Average Return on Invested Capital over 5 years is 0.58%, with a median of 0.38% recorded in 2022.
  • The sharpest move saw Return on Invested Capital surged 759bps in 2024, then tumbled -694bps in 2025.
  • Year by year, Return on Invested Capital stood at 1.28% in 2021, then skyrocketed by 126bps to 0.33% in 2022, then skyrocketed by 33bps to 0.44% in 2023, then crashed by -896bps to 3.49% in 2024, then soared by 121bps to 0.74% in 2025.
  • Business Quant data shows Return on Invested Capital for URGN at 0.74% in Q4 2025, 0.64% in Q3 2025, and 0.81% in Q2 2025.